270 related articles for article (PubMed ID: 9663810)
1. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
Dingemanse J; Kneer J; Wallnöfer A; Kettler R; Zürcher G; Koulu M; Korn A
Clin Neuropharmacol; 1996 Oct; 19(5):399-414. PubMed ID: 8889283
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
[TBL] [Abstract][Full Text] [Related]
4. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
Zimmer R
Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of clonidine on tyramine- and methoxamine-evoked mydriasis in man.
Bitsios P; Langley RW; Szabadi E; Bradshaw CM
Br J Clin Pharmacol; 1996 Apr; 41(4):269-75. PubMed ID: 8730971
[TBL] [Abstract][Full Text] [Related]
6. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
Holford NH; Guentert TW; Dingemanse J; Banken L
Br J Clin Pharmacol; 1994 May; 37(5):433-9. PubMed ID: 7519866
[TBL] [Abstract][Full Text] [Related]
7. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations.
Dingemanse J; Korn A; Pfefen JP; Güntert TW
Psychopharmacology (Berl); 1992; 106 Suppl():S46-8. PubMed ID: 1347659
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
[TBL] [Abstract][Full Text] [Related]
9. Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline.
Korn A; Wagner B; Moritz E; Dingemanse J
Eur J Clin Pharmacol; 1996; 49(4):273-8. PubMed ID: 8857072
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
Goren T; Adar L; Sasson N; Weiss YM
J Clin Pharmacol; 2010 Dec; 50(12):1420-8. PubMed ID: 20445015
[TBL] [Abstract][Full Text] [Related]
11. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
Gerardy J
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
Berlin I; Zimmer R; Thiede HM; Payan C; Hergueta T; Robin L; Puech AJ
Br J Clin Pharmacol; 1990 Dec; 30(6):805-16. PubMed ID: 1705137
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
Wiesel FA; Raaflaub J; Kettler R
Eur J Clin Pharmacol; 1985; 28(1):89-95. PubMed ID: 3987791
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
15. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
[TBL] [Abstract][Full Text] [Related]
16. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.
Finberg JP; Youdim MB
Br J Pharmacol; 1985 Jun; 85(2):541-6. PubMed ID: 3928010
[TBL] [Abstract][Full Text] [Related]
17. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid.
Humphrey SJ; Curry JT; Turman CN; Stryd RP
J Cardiovasc Pharmacol; 2001 May; 37(5):548-63. PubMed ID: 11336106
[TBL] [Abstract][Full Text] [Related]
19. Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.
Cusson JR; Goldenberg E; Larochelle P
J Clin Pharmacol; 1991 May; 31(5):462-7. PubMed ID: 2050833
[TBL] [Abstract][Full Text] [Related]
20. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
Van Haarst AD; Van Gerven JM; Cohen AF; De Smet M; Sterrett A; Birk KL; Fisher AL; De Puy ME; Goldberg MR; Musson DG
Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]